

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Actinic cheilitis, 123–124
- Addison disease, 175
- Adenopathy, due to *Mycobacterium tuberculosis*, 6
 - from histoplasmosis abscess, 6
- Alveolar bone, damage to, in smokeless tobacco use, 41–42
- Aminoglycosides, 68
- Amyloidosis, 169
 - oral manifestations of, 186–187
- Anaerobic bacteria, 25
- Anemia, 21
 - iron-deficiency, 161–162, 188–189
 - megaloblastic, 189
 - pernicious, 162, 163
- Aneurin, 192
- Angiotensin-converting enzyme inhibitors, pemphigus and, 135
- Anorexia nervosa, 198–199
- Antibacterials, in oral infections, 62–71
- Antibiotic therapy, oral infections and, **57–78**
- Antidepressants, in burning mouth syndrome, 212
- Antifungals, 71–72
 - for oral candidiasis, 238
- Antivirals, 72
- Aphthous stomatitis, clinical presentation of, 79–80
 - conditions and causative factors associated with, 82–83
 - epidemiology of, 80, 81
 - etiology of, 80–81
 - management of, 83–85
 - recurrent, **79–88**
- Aphthous ulcer, 8
- Ascorbate, 195–196
- Ascorbic acid, 195–196
- L-Ascorbic acid, 195–196
- Aspirin burn injury, 11
- Autoimmune conditions, oral manifestations of, 165–169
- Azoles, 71–72
- Aztreonam, 68

B

- Bacteria, in oral cavity, 59
- Biomarkers, in screening and diagnostic testing, 20–21

- Biopsy, of mucosal lesions, 26
- Biotin, 194
- Bone, invasion by squamous cell carcinoma, 12
- Brush cytology, in screening and diagnostic testing, 19–20
- Buccal mucosa, examination of, 10–11
 - leukoedema of, 11
- Bulimia nervosa, 198–199
- Bullous diseases, oral intramucosal, 133–142
 - oral submucosal, 142–152
- Bullous pemphigoid, 145–148
- Burning mouth syndrome, and hormonal disturbances, 208
 - and psychiatric disease, 208
 - and secondary oral burning, **205–219**
 - compared, 209
 - as central neuropathy, 207
 - as peripheral neuropathy, 206–207
 - as phantom pain, 207–208
 - as variable disorder with subcategories, 208
 - epidemiology of, 206
 - etiology of, 206–209
 - evaluation and diagnosis of, 209, 210
 - prognosis in, 209
 - symptoms of, 205–206
 - treatment of, 209–215

C

- Calciferol, 197
- Cancer, oral, early detection of, 222
 - and premalignant lesions in, **221–229**
 - supravital staining for, 222–223
 - in smokeless tobacco users, 44–48
 - optical detection of, 223–224
 - techniques for, 224–227
- Candidiasis, acute atrophic, 232–233
 - and immunocompromised host, 235
 - chronic atrophic, 233
 - chronic mucocutaneous, 235
 - chronic multifocal, 234
 - HIV-associated, 235–236
 - hyperplastic, 234–235
 - oral, clinical manifestations of, 232–236
 - diagnosis of, 236–237
 - and management of, **231–240**
 - management of, 237–238
 - predisposing factors for, 231–232
- Carbapenems, 67–68
- Carcinoma, squamous cell. *See Squamous cell carcinoma.*
- Castleman disease, 6
- CBC measurements, 24
- Cephalosporins, 64–67

Download English Version:

<https://daneshyari.com/en/article/4124287>

Download Persian Version:

<https://daneshyari.com/article/4124287>

[Daneshyari.com](https://daneshyari.com)